Compare Johnson & Johnson (JNJ) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Teradyne, Inc. — how do they compare? Johnson & Johnson trades at $260.33 (market cap $626.09B), while Teradyne, Inc. trades at $403.15 (market cap $59.34B). The key difference: Johnson & Johnson is far larger — about 10.6× Teradyne, Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| JNJ | TER | |
|---|---|---|
Market Cap | $626.09B | $59.34B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $483.84 |
52-Week Low | $172.78 | $109.30 |
Enterprise Value | $654.37B | $59.09B |
Dividend Yield | 2.06% | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Teradyne (TER) trades at $365.10, down 3.75% on the day despite strong Q2 2026 earnings that beat expectations with EPS of $2.47 versus $2.09 forecast. The stock shows neutral technical signals with support at $358 and resistance at $380, while fundamentals remain robust with 25.77% net margins and 36.66% ROE. Recent news highlights AI-driven semiconductor test demand fueling record revenues.
Outlook remains positive with analyst consensus price target of $481.63 (32% upside) and no sell ratings. Key risks include premium valuation (P/E 52.14) and dependence on semiconductor cycle volatility. Strong institutional ownership and consistent earnings beats support bullish sentiment for long-term growth in AI and robotics markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
